Top Markets
#1 Helium Helium +111.70%
#2 MowCat MowCat +87.96%
#3 Seeker Seeker +59.64%
#4 UnifAI Network UnifAI Network +35.38%
#5 TENDIES TENDIES +30.15%
#6 pipedog pipedog +23.48%
#7 Zylo Ecosystem Zylo Ecosystem +22.00%
#8 Bounce Bounce +20.25%
#9 Tensor Tensor +19.72%
#10 Pons Pons +19.15%
Coin of the day
Helium Helium
Pengaturan
Bahasa
BAHASA INDONESIA
Mata uang
USD
Tema
Poseida Therapeutics, Inc. Poseida Therapeutics, Inc.

Poseida Therapeutics, Inc.

PSTX
Peringkat dalam Saham #10560
Poseida Therapeutics, Inc., a San Diego-based clinical-stage biopharmaceutical... Poseida Therapeutics, Inc., a San Diego-based clinical-stage biopharmaceutical firm established in 2014, is dedicated to advancing novel therapeutic solutions for conditions with significant unmet medical needs. Its pipeline prominently features several advanced cell therapies. For instance, P-PSMA-101, an autologous CAR-T cell therapy, is currently undergoing Phase I clinical trials for individuals battling metastatic castrate-resistant prostate cancer (mCRPC). Additionally, Poseida is progressing two other CAR-T candidates through Phase I: P-BCMA-ALLO1 targets relapsed/refractory multiple myeloma, while P-MUC1C-ALLO1 is designed to address a variety of solid tumors, such as breast, ovarian, and other epithelial-derived malignancies. The company is further exploring allogeneic (off-the-shelf) CAR-T approaches with candidates like P-CD19CD20-ALLO1, aimed at B cell malignancies and certain autoimmune conditions, and P-BCMACD19-ALLO1, which is in preclinical development for multiple myeloma. Another allogeneic CAR-T, P-PSMA-ALLO1, is also being developed for mCRPC. Beyond cell therapies, Poseida's portfolio includes clinical-stage liver-directed gene therapies, specifically P-OTC-101 and P-FVIII-101, alongside other exploratory allogeneic dual CAR candidates. Collaborative efforts include a research and licensing agreement with Takeda Pharmaceutical Company Limited.
Harga Saham
$9.50
Terakhir disinkronkan: 2025-01-08
Kapitalisasi Pasar
$819.52M
Perubahan (1 hari)
0.00%
Perubahan (1 tahun)
0.00%
Negara
US
Perdagangan Poseida Therapeutics, Inc. (PSTX)

Kategori

Healthcare
Laba untuk Poseida Therapeutics, Inc. (PSTX)
Laba pada Sep 2024 TTM: $-60.72M
Menurut laporan keuangan terbaru dari Poseida Therapeutics, Inc., laba saat ini perusahaan adalah $-60.72M. Pada tahun 2022, perusahaan memperoleh laba sebesar $-63.46M, penurunan dibandingkan dengan laba tahun 2021 sebesar $-124.97K. Laba yang ditampilkan di halaman ini adalah laba sebelum bunga dan pajak, atau disebut juga EBIT.
Riwayat laba untuk Poseida Therapeutics, Inc. dari 2016 hingga 2026
Laba pada akhir setiap tahun
Tahun Laba Mengubah
2026 (TTM) $-60.72M -50.77%
2023 $-123.32M 94.34%
2022 $-63.46M 50,676.96%
2021 $-124.97K -3.70%
2020 $-129.78K -99.85%
2019 $-86.53M 93.98%
2018 $-44.61M 120.94%
2017 $-20.19M 278.07%
2016 $-5.34M 0.00%
Laba untuk perusahaan serupa atau pesaing
Perusahaan Laba Perbedaan Laba Negara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -8,787.83%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -3,312.74%
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
$-4.02B 6,514.73%
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
$-3.09B 4,984.33%
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH